Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma

Frequently described immune-mediated adverse effects of immune therapy include dermatological complications, hepatitis, colitis, pneumonitis, and endocrinopathies. As utilization of pembrolizumab and related agents continues to expand both in the available indications as well as duration of exposure...

Descripción completa

Detalles Bibliográficos
Autores principales: Khokhar, Muhammad O., Kettle, Jacob, Palla, Amruth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216251/
https://www.ncbi.nlm.nih.gov/pubmed/28101032
http://dx.doi.org/10.1159/000452944
_version_ 1782491889746837504
author Khokhar, Muhammad O.
Kettle, Jacob
Palla, Amruth R.
author_facet Khokhar, Muhammad O.
Kettle, Jacob
Palla, Amruth R.
author_sort Khokhar, Muhammad O.
collection PubMed
description Frequently described immune-mediated adverse effects of immune therapy include dermatological complications, hepatitis, colitis, pneumonitis, and endocrinopathies. As utilization of pembrolizumab and related agents continues to expand both in the available indications as well as duration of exposure, there remains a significant potential to uncover previously undescribed adverse events. From a dermatological standpoint, 39% of patients receiving pembrolizumab therapy experience some form of skin-related drug toxicity [Naidoo et al.: Ann Oncol 2015;26: 2375–2391]. We describe a case of pembrolizumab-induced disabling autoimmune ectodermal toxicity.
format Online
Article
Text
id pubmed-5216251
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-52162512017-01-18 Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma Khokhar, Muhammad O. Kettle, Jacob Palla, Amruth R. Case Rep Oncol Case Report Frequently described immune-mediated adverse effects of immune therapy include dermatological complications, hepatitis, colitis, pneumonitis, and endocrinopathies. As utilization of pembrolizumab and related agents continues to expand both in the available indications as well as duration of exposure, there remains a significant potential to uncover previously undescribed adverse events. From a dermatological standpoint, 39% of patients receiving pembrolizumab therapy experience some form of skin-related drug toxicity [Naidoo et al.: Ann Oncol 2015;26: 2375–2391]. We describe a case of pembrolizumab-induced disabling autoimmune ectodermal toxicity. S. Karger AG 2016-12-08 /pmc/articles/PMC5216251/ /pubmed/28101032 http://dx.doi.org/10.1159/000452944 Text en Copyright © 2016 the Author(s) http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Khokhar, Muhammad O.
Kettle, Jacob
Palla, Amruth R.
Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma
title Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma
title_full Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma
title_fullStr Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma
title_full_unstemmed Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma
title_short Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma
title_sort debilitating skin toxicity associated with pembrolizumab therapy in an 81-year-old female with malignant melanoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216251/
https://www.ncbi.nlm.nih.gov/pubmed/28101032
http://dx.doi.org/10.1159/000452944
work_keys_str_mv AT khokharmuhammado debilitatingskintoxicityassociatedwithpembrolizumabtherapyinan81yearoldfemalewithmalignantmelanoma
AT kettlejacob debilitatingskintoxicityassociatedwithpembrolizumabtherapyinan81yearoldfemalewithmalignantmelanoma
AT pallaamruthr debilitatingskintoxicityassociatedwithpembrolizumabtherapyinan81yearoldfemalewithmalignantmelanoma

Ejemplares similares